After nearly eight years of platform development and treatment of more than 200 patients across six clinical studies, Allogene has built an off-the-shelf CAR T platform designed to deliver clinical utility, broad patient access, predictable manufacturing, and scalable economics. The company has achieved a burn rate 28% lower than its 2023 peak with runway spanning two pivotal data-readout years, which buys ALLO time to execute without needing dilutive financing.
Cyborg Score Rationale
With a cash runway to 2027 and 2026's dual catalysts, ALLO offers a rare combination of safety and upside. However, the company faces significant financial headwinds with minimal revenue and substantial losses. Success depends entirely on 2026 clinical trial results.
Top Insights
Interim futility analysis of MRD clearance from the pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) expected in 1H 2026
Initial ALLO-329 proof-of-concept data expected by the end of 1H 2026 for autoimmune applications
Company targets ~30,000–60,000+ doses annually with COGS of <$10K–20K per dose, enabling biologic-like scale economics
Favorable arbitration regarding Cema-Cel secures ALLO's control over critical IP, enhancing its commercial prospects
Named Competitors
Yescarta — Autologous CAR-T for large B-cell lymphoma
Kymriah — Autologous CAR-T for B-ALL and lymphoma
Tecartus — Autologous CAR-T for mantle cell lymphoma
Recent Developments
(December 2025) Favorable arbitration result for Servier against Cellectis, securing control over cema-cel intellectual property
(January 2026) Multiple analyst upgrades including UBS Buy rating with $8 price target, spurring 15.44% stock appreciation
(March 2026) Announced Q4 2025 earnings release scheduled for March 12, 2026, positioning for 1H 2026 catalyst stack
Open the full interactive Allogene Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.